XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Reportable Segment Information
9 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Reportable Segment Information

 

NOTE Q – REPORTABLE SEGMENT INFORMATION

Ashland determines its reportable segments based on how operations are managed internally for the products and services sold to customers, including how the results are reviewed by the chief operating decision maker, which includes determining resource allocation methodologies used for reportable segments. Operating income and EBITDA are the primary measures of performance that are reviewed by the chief operating decision maker in assessing each reportable segment's financial performance. Ashland does not aggregate operating segments to arrive at these reportable segments.

Change in Reportable Segments

During the second quarter of fiscal year 2020, Ashland changed the manner in which it manages the business moving from a functionally led to a business led organization. This change recognizes that Ashland has a diverse portfolio of businesses with different value propositions for the markets Ashland serves. The organizational change allows Ashland to align its business models, resources and cost structure to the specific needs of each business and enables greater ownership and accountability for both short- and long-term performance. Ashland has realigned its segment reporting structure commensurate with this organizational change. As a result, Ashland’s five reportable segments include the consumer specialty businesses: Life Sciences and Personal Care & Household; the industrial specialty businesses: Specialty Additives and Performance Adhesives; and Intermediates and Solvents. Corporate includes corporate governance activities and certain legacy matters.  The historical segment information has been recast to conform to the current segment structure.  

  

 

Reportable segment business descriptions

Consumer Specialties

Life Sciences is comprised of pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, advanced materials and fine chemicals. Pharmaceutical solutions include controlled release polymers, disintegrants, film coatings, solubilizers, and tablet binders. Nutrition solutions include thickeners, stabilizers, emulsifiers and additives for enhancing mouthfeel, controlling moisture migration, reducing oil uptake and controlling color. Nutraceutical solutions include products for weight management, joint comfort, stomach and intestinal health, sports nutrition and general wellness, and providing custom formulation, toll processing and particle engineering solutions. Customers include pharmaceutical, food, beverage, nutraceuticals and supplements manufacturers, hospitals and radiologists and industrial manufacturers.

Personal Care & Household is comprised of biofunctionals, preservatives, skin care, sun care, oral care, hair care and household. These businesses have a broad range of nature-based, biodegradable, and performance-enhancing ingredients for customer-driven solutions to help protect, renew, moisturize and revitalize skin and hair, and provide solutions for toothpastes, mouth washes and rinses, denture cleaning and care for teeth. Household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers for household, industrial and institutional cleaning products.  Customers include formulators at large multinational branded consumer products companies and smaller, independent boutique companies.

Industrial Specialties

Specialty Additives is comprised of rheology- and performance-enhancing additives serving the coatings, construction, energy, automotive and various industrial markets. Solutions include coatings additives for architectural paints, finishes and lacquers, cement- and gypsum- based dry mortars, ready-mixed joint compounds, synthetic plasters for commercial and residential construction, and specialty materials for industrial applications.  Products include rheology modifiers (cellulosic and associative thickeners), foam-control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, and environmental filters, ingredients that aid the manufacturing process of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding. Products help improve desired functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition and suspension and emulsification. Customers include global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry, and welders.

Performance Adhesives is comprised of adhesives used in packaging, converting and structural applications. Packaging adhesives has an extensive line of pressure sensitive adhesives, functional coatings and primers combined with innovative technology solutions for narrow-, mid- and wide-web applications. Products meet stringent requirements in food and beverage safety, shipping, transportation, health and beauty, industrial, postage and security printing. Structural adhesives include light weighting vehicles and eliminating VOCs in buildings. Customers include converters of packaging materials, manufacturers of building materials and tier one suppliers to transportation industry.

Other

Intermediates and Solvents is comprised of the production of 1,4 butanediol (BDO) and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. Butanediol is also provided to Life Sciences, Personal Care, and Specialty Additives for use as a raw material.

Unallocated and Other generally includes items such as certain significant company-wide restructuring activities, corporate governance costs and legacy costs or activities that relate to divested businesses that are no longer operated by Ashland.

Reportable segment results

Results of Ashland’s reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland’s reportable segments are not necessarily comparable with similar information for other comparable companies. Ashland allocates all significant costs to its reportable segments except for certain significant company-wide restructuring activities, certain corporate governance costs and other costs or activities that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit income caption on the Statements of Consolidated Comprehensive Income (Loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as internal accounting practices are improved, more refined information becomes available and the industry or market changes. Significant revisions to Ashland’s methodologies are adjusted for all segments on a retrospective basis. This includes charges in the current fiscal year for certain corporate governance costs, which were previously allocated. These costs are now reflected in Unallocated and Other for all periods presented.

The following table presents various financial information for each reportable segment for the three and nine months ended June 30, 2020 and 2019.

 

Three months ended

 

 

Nine months ended

 

 

June 30

 

 

June 30

 

(In millions - unaudited)

2020

 

 

2019

 

 

2020

 

 

2019

 

SALES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

189

 

 

$

190

 

 

$

528

 

 

$

556

 

Personal Care & Household

 

155

 

 

 

158

 

 

 

451

 

 

 

495

 

Consumer Specialties

 

344

 

 

 

348

 

 

 

979

 

 

 

1,051

 

Specialty Additives

 

135

 

 

 

177

 

 

 

429

 

 

 

494

 

Performance Adhesives

 

70

 

 

 

88

 

 

 

229

 

 

 

258

 

Industrial Specialties

 

205

 

 

 

265

 

 

 

658

 

 

 

752

 

Intermediates and Solvents

 

37

 

 

 

41

 

 

 

102

 

 

 

118

 

Intersegment sales (a)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Intermediates and Solvents

 

(12

)

 

 

(13

)

 

 

(22

)

 

 

(37

)

 

$

574

 

 

$

641

 

 

$

1,717

 

 

$

1,884

 

OPERATING INCOME (LOSS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

40

 

 

$

32

 

 

$

97

 

 

$

88

 

Personal Care & Household

 

16

 

 

 

17

 

 

 

(309

)

 

 

60

 

Consumer Specialties

 

56

 

 

 

49

 

 

 

(212

)

 

 

148

 

Specialty Additives

 

15

 

 

 

19

 

 

 

(137

)

 

 

(5

)

Performance Adhesives

 

13

 

 

 

16

 

 

 

40

 

 

 

42

 

Industrial Specialties

 

28

 

 

 

35

 

 

 

(97

)

 

 

37

 

Intermediates and Solvents

 

7

 

 

 

8

 

 

 

(7

)

 

 

20

 

Unallocated and other

 

(43

)

 

 

(49

)

 

 

(87

)

 

 

(125

)

 

$

48

 

 

$

43

 

 

$

(403

)

 

$

80

 

DEPRECIATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

8

 

 

$

8

 

 

$

24

 

 

$

24

 

Personal Care & Household

 

10

 

 

 

10

 

 

 

30

 

 

 

30

 

Consumer Specialties

 

18

 

 

 

18

 

 

 

54

 

 

 

54

 

Specialty Additives

 

15

 

 

 

15

 

 

 

46

 

 

 

84

 

Performance Adhesives

 

4

 

 

 

4

 

 

 

10

 

 

 

11

 

Industrial Specialties

 

19

 

 

 

19

 

 

 

56

 

 

 

95

 

Intermediates and Solvents

 

4

 

 

 

3

 

 

 

10

 

 

 

8

 

Unallocated and other

 

 

 

 

 

 

 

 

 

 

3

 

 

$

41

 

 

$

40

 

 

$

120

 

 

$

160

 

 

AMORTIZATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

7

 

 

$

7

 

 

$

21

 

 

$

21

 

Personal Care & Household

 

9

 

 

 

10

 

 

 

27

 

 

 

28

 

Consumer Specialties

 

16

 

 

 

17

 

 

 

48

 

 

 

49

 

Specialty Additives

 

5

 

 

 

5

 

 

 

14

 

 

 

14

 

Performance Adhesives

 

 

 

 

 

 

 

1

 

 

 

1

 

Industrial Specialties

 

5

 

 

 

5

 

 

 

15

 

 

 

15

 

Intermediates and Solvents

 

 

 

 

 

 

 

 

 

 

1

 

 

$

21

 

 

$

22

 

 

$

63

 

 

$

65

 

EBITDA (b) (c)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

55

 

 

$

47

 

 

$

142

 

 

$

133

 

Personal Care & Household

 

35

 

 

 

37

 

 

 

(252

)

 

 

118

 

Consumer Specialties

 

90

 

 

 

84

 

 

 

(110

)

 

 

251

 

Specialty Additives

 

35

 

 

 

39

 

 

 

(77

)

 

 

93

 

Performance Adhesives

 

17

 

 

 

20

 

 

 

51

 

 

 

54

 

Industrial Specialties

 

52

 

 

 

59

 

 

 

(26

)

 

 

147

 

Intermediates and Solvents

 

11

 

 

 

11

 

 

 

3

 

 

 

29

 

Unallocated and other

 

(43

)

 

 

(49

)

 

 

(83

)

 

 

(122

)

 

$

110

 

 

$

105

 

 

$

(216

)

 

$

305

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30, 2020

 

 

September 30, 2019

 

TOTAL ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

 

 

 

 

 

 

 

 

$

1,979

 

 

$

1,946

 

Personal Care & Household

 

 

 

 

 

 

 

 

 

979

 

 

 

1,366

 

Consumer Specialties

 

 

 

 

 

 

 

 

 

2,958

 

 

 

3,312

 

Specialty Additives

 

 

 

 

 

 

 

 

 

1,642

 

 

 

1,775

 

Performance Adhesives

 

 

 

 

 

 

 

 

 

595

 

 

 

618

 

Industrial Specialties

 

 

 

 

 

 

 

 

 

2,237

 

 

 

2,393

 

Intermediates and Solvents

 

 

 

 

 

 

 

 

 

164

 

 

 

185

 

Unallocated and other

 

 

 

 

 

 

 

 

 

1,627

 

 

 

1,361

 

 

 

 

 

 

 

 

 

 

$

6,986

 

 

$

7,251

 

 

 

(a)

Intersegment sales from Intermediates and Solvents are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.

 

(b)

Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.

 

(c)

Includes $39 million of accelerated depreciation for the nine months ended June 30, 2019.